Even at $2M+, ICER calls blue­bird's po­ten­tial gene ther­a­py for blood dis­or­der 'su­pe­ri­or' to stan­dard of care

4 years ago
Pharma
Cell/Gene Tx

Bear mar­ket forces an­oth­er biotech in­to lay­offs, as an­ti­body de­vel­op­er Atre­ca re­duces head­count by more than 25%

4 years ago
People

Roche wa­gers $180M in quick cash on a can­di­date for best-in-class tu­mor tar­get­ing drug

4 years ago
R&D

Michael Sev­eri­no trades in Ab­b­Vie perch for CEO role at Flag­ship’s gene med­i­cines biotech Tessera

4 years ago
People
Startups

Pas­cal So­ri­ot's big year at the helm of As­traZeneca is crowned with a knight­hood

4 years ago
People

Saman­tha Truex of­fi­cial­ly un­wraps Up­stream Bio, her se­cre­tive, Or­biMed-backed biotech with $200M in the bank

4 years ago
People
Financing

Ab­b­Vie in po­si­tion to be­come largest phar­ma by 2028, nar­row­ly edg­ing out Roche — re­port

4 years ago
Pharma

Long­time Pfiz­er vet tapped to re­place leg­endary vac­cine re­searcher Kathrin Jansen

4 years ago
Pharma

BMS, Mi­rati fund new Stand Up To Can­cer re­search teams, adding to list of phar­ma part­ner­ships

4 years ago
Pharma
Marketing

Bavar­i­an Nordic con­tin­ues to in­crease 2022 rev­enue pro­jec­tions as mon­key­pox spreads

4 years ago
Pharma
Manufacturing

Chang­ing course, Pfiz­er de­cides to sell off stake in GSK's con­sumer health spin­off

4 years ago
Pharma

FDA+ roundup: Medicare spends bil­lions on un­con­firmed ac­cel­er­at­ed ap­provals — study; EMA ap­points new CMO

4 years ago
FDA+

Talk to your doc­tor? Phar­ma TV ads are still spurring pa­tients to ac­tion, study finds

4 years ago
Pharma
Marketing

FDA's Pe­ter Marks lays out plans to sup­port gene ther­a­pies for ul­tra-rare dis­eases

4 years ago
Cell/Gene Tx
FDA+

Bay Area ge­nomics start­up emerges from stealth with $600M in the bank and promis­ing a '$100 genome' test

4 years ago
Startups
Diagnostics

FDA lifts hold on Leg­end Biotech's fol­low-up CAR-T tar­get­ing CD4+

4 years ago
R&D
FDA+

Trail­ing As­traZeneca in lu­pus, Bris­tol My­ers looks to push TYK2 drug in­to PhI­II tri­als

4 years ago
R&D

Sage and Bio­gen build out case for de­pres­sion drug as it pass­es PhI­II test in post­par­tum women

4 years ago
R&D

FDA cites in­creased death risk in de­ci­sion to yank ap­proval for TG Ther­a­peu­tics can­cer drug

4 years ago
FDA+

Pas­sage Bio CEO de­parts af­ter March lay­offs as biotech goes with le­gal chops for in­ter­im re­place­ment

4 years ago
People

'Vac­cines alone are in­suf­fi­cien­t': Mer­ck, Ali­gos work with aca­d­e­m­ic ex­perts to find Covid an­tivi­rals as part of $65M ...

4 years ago
Discovery
Coronavirus

Once a GSK hope­ful for heart dis­ease, an in­hibitor class makes a come­back in Alzheimer's deal

4 years ago
Deals

Sanofi earns break­through nod in he­mo­phil­ia A as it con­tin­ues to play catch-up with Roche's Hem­li­bra

4 years ago
R&D
FDA+

Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

4 years ago
Deals
First page Previous page 521522523524525526527 Next page Last page
A service from the Financial Times